These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7749985)

  • 1. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
    Zhou H; Glimcher LH
    Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome).
    Steimle V; Otten LA; Zufferey M; Mach B
    Cell; 1993 Oct; 75(1):135-46. PubMed ID: 8402893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant.
    Zhou H; Su HS; Zhang X; Douhan J; Glimcher LH
    J Immunol; 1997 May; 158(10):4741-9. PubMed ID: 9144488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
    Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
    Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.
    Masternak K; Muhlethaler-Mottet A; Villard J; Zufferey M; Steimle V; Reith W
    Genes Dev; 2000 May; 14(9):1156-66. PubMed ID: 10809673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.
    Masternak K; Reith W
    EMBO J; 2002 Mar; 21(6):1379-88. PubMed ID: 11889043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation in the class II trans-activator leading to a mild immunodeficiency.
    Wiszniewski W; Fondaneche MC; Le Deist F; Kanariou M; Selz F; Brousse N; Steimle V; Barbieri G; Alcaide-Loridan C; Charron D; Fischer A; Lisowska-Grospierre B
    J Immunol; 2001 Aug; 167(3):1787-94. PubMed ID: 11466404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
    Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
    PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.
    Long AB; Ferguson AM; Majumder P; Nagarajan UM; Boss JM
    Mol Immunol; 2006 Feb; 43(5):395-409. PubMed ID: 16337482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.
    Deffrennes V; Vedrenne J; Stolzenberg MC; Piskurich J; Barbieri G; Ting JP; Charron D; Alcaïde-Loridan C
    J Immunol; 2001 Jul; 167(1):98-106. PubMed ID: 11418637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of MHC class II gene expression in a patient with a single amino acid substitution in the class II transactivator protein CIITA.
    Quan V; Towey M; Sacks S; Kelly AP
    Immunogenetics; 1999 Oct; 49(11-12):957-63. PubMed ID: 10501838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
    Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
    J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DN alpha/DO beta heterodimer.
    Taxman DJ; Cressman DE; Ting JP
    J Immunol; 2000 Aug; 165(3):1410-6. PubMed ID: 10903745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.
    Peijnenburg A; Van den Berg R; Van Eggermond MJ; Sanal O; Vossen JM; Lennon AM; Alcaïde-Loridan C; Van den Elsen PJ
    Immunogenetics; 2000 Jan; 51(1):42-9. PubMed ID: 10663561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA).
    Riley JL; Westerheide SD; Price JA; Brown JA; Boss JM
    Immunity; 1995 May; 2(5):533-43. PubMed ID: 7749984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.
    Scholl T; Mahanta SK; Strominger JL
    Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6330-4. PubMed ID: 9177217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator.
    Douhan J; Lieberson R; Knoll JH; Zhou H; Glimcher LH
    J Exp Med; 1997 Jun; 185(11):1885-95. PubMed ID: 9166418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.
    Hauber I; Gulle H; Wolf HM; Maris M; Eggenbauer H; Eibl MM
    J Exp Med; 1995 Apr; 181(4):1411-23. PubMed ID: 7699327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain.
    Yun S; Gustafsson K; Fabre JW
    Transplantation; 1998 Jul; 66(1):103-11. PubMed ID: 9679829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
    Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
    Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.